J&J acquired rights to TAR-200 when it bought privately-owned biotech Taris for an undisclosed sum in 2019, and has big sales ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's ...

For our final liveblog day we’re back at the Informa Biotech Showcase for more packed panels on AI and funding, a panel on ...

Continued pricing pressures from governments and patient groups are driving small molecule CDMOs to focus on reducing the ...

In today’s pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Isaac Bentwich, CEO and founder of Quris.AI, about ...

The action affects the TROPOS trial of cibotacept (KER-012), an activin signalling inhibitor that works in a similar way to ...

This journey, however, has also revealed the challenges inherent in achieving healthcare equity, particularly in bridging the ...

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity ...